2020-2027 Analysis and Review Tacrolimus Market

Tacrolimus Market

Tacrolimus Market by Clinical Application (Immunosuppressant, Dermatology and Others) by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

25-07-2020 REP-HC-5143 40 Tables 120 pages Format

The tacrolimus market was valued at USD 2,388.5 Mn by 2019. The constant rise in the number of individuals undergoing solid organ transplant worldwide primarily drives the tacrolimus market growth. Additionally, the increasing prescription of tacrolimus for the treatment of psoriasis and eczema across the globe further accentuates the market growth.

Tacrolimus Market

Tacrolimus is also known as fujimycin or FK-506 is classified as an immunosuppressant drug which is widely employed to suppress the immune system of patients which are undergoing organ transplant in order to reduce the risk of organ rejection. It exhibits its activity by reducing peptidyl-prolyl isomerase activity chiefly by interacting with FKBP-12 creating a new complex that then inhibits IL-2 transcription and T-lymphocyte signal transduction.

The major segments related to the tacrolimus market are: 

By Clinical Application (2017–2027; US$ Mn)

Immunosuppressant

Dermatology

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global tacrolimus market
  • The overall segmentation of the tacrolimus market, by clinical application, distribution channel, and geography is minutely studied. Immunosuppressant and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
  • Significant increase in the number of individuals undergoing organ transplant worldwide
  • Rising prevalence of dermatology complications such as eczema, psoriasis, etc., further accentuates the market growth

Report gist?

  • The study of the global tacrolimus market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of tacrolimus due to the significant increase in the number of individuals undergoing organ transplant worldwide
  • The report will benefit dermatologist prescribing tacrolimus for the treatment of eczema and psoriasis across the globe
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to tacrolimus market
  • Financial institutions, venture capitalists, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies. 

Segment Analysis

An immunosuppressant is reigning the clinical application segment for the tacrolimus market. A significant increase in the number of people undergoing organ transplants worldwide primarily drives the tacrolimus market growth as an immunosuppressant drug. According to the latest statistics provided by the World Health Organization (WHO), approximately 100, 800 solid organ transplants are done each year across the globe. Rising prevalence of autoimmune diseases requiring immunosuppressant as a first-line therapy further accentuates the market growth. Dermatology complications are set to showcase exemplary market performance during the forecast period on account of the rising prevalence of skin complications in the people residing in the sub-tropical climates throughout the globe. As per the recent clinical findings presented by the National Psoriasis Foundation (NPF), approximately 125 million people worldwide are reported to be suffering from psoriasis. According to the latest information brought forward by the European Society for Medical Oncology (ESMO), it is estimated that eczema affects 1% to 3% of the global population.

Hospital pharmacy is currently representing the largest market share in the distribution channel segment for tacrolimus market. Drug-related adverse events such as nausea, headache, renal complications, skin sensitization, etc. make it necessary for the precise drug compounding of tacrolimus in the presence of a hospital pharmacist. Retail pharmacy is keen to register magnificent market growth in the near future on account of its ability to provide low-cost essential medicines due to government subsidy on generic drugs and capacity to fulfill the medicinal requirements of households residing in the remote locations.

North America is presently spearheading the geography segment for the tacrolimus market. The rising prevalence of dermatology complications primarily drives the tacrolimus market growth in the region. As per the latest research citings provided by the National Psoriasis Foundation (NPF), approximately 8 million Americans are suffering from psoriasis. Additionally, the existence of developed healthcare infrastructure and affordable reimbursement scenarios pertaining to tacrolimus products further propels the market growth in the region. Europe is considered the second-largest regional segment for the tacrolimus market on account of the domicile of key players such as GlaxoSmithKline, Plc., Astellas Pharma, Inc., Chiesi Farmaceutici, etc. Additionally, the nurturing regulatory environment provided by the European Medical Agency (EMA), for the sale and distribution of tacrolimus further accentuates the market growth in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for the tacrolimus market on account of the rising prevalence of eczema across all age groups and flourishing generic drugs market.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.